Ann: SPP offer documents issued to shareholders, page-2

Hi All, well, this is not ideal to be raising at this SP, but fundamentally CHM is stronger and we an opportunity to buy in lower. Glad no options attached so we dont see selling of the heads and keeping the oppies. I'll be taking my allocation to help the company directly

Looks like according to below, CHM has recently had a positive pre-IND meeting for CDH17 CHM 2101 hopefully close to getting in the clinic now. This U penn asset has always been an exciting third gen Car-T for mine with exceptional pre-clinical data.

While we wait for some more data from the company, If anyone would like to read an amazing book on the science of cancer treatment and how the immune system works (especially lymphocytes - B and T cells) highly recommend "The breakthrough" by Charles Graeber. If also shows inspiring case studies of real patients who were lucky enough to have access to successful clinical trials. Fascinating to see things from the patient side. It talks about Carl June from U Penn who helped invent Car-T. It was written in 2018 but still gives a great insight into immunotherapy and its origins.

Value will be realised here just need some more patience.